Literature DB >> 8967969

Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.

A J Stewart1, C Pichon, L Meunier, P Midoux, M Monsigny, A C Roche.   

Abstract

We sought to exploit glycosylated poly-L-lysine (pLK) to increase the uptake and biological antisense activity of a phosphorothioate oligonucleotide (pt-odn) [pt-odn complementary to the 3' noncoding region of intercellular adhesion molecule-1 (ICAM-1) (odn(ICAM-1))] complementary to the 3'-noncoding region of ICAM-1 in A549 cells. Dose-dependent inhibition of ICAM-1 expression was obtained (IC50 = 500 nM) through treatment of cells with odn(ICAM-1) complexed with pLK carrying fucose residues in the presence of 100 microM chloroquine. Alteration in the charge ratio between fucosylated pLK and pt-odn had a significant effect on the efficacy of inhibition (optimal conditions, charge ratio = 1.1). This effect was also dependent on the number of fucose moieties per pLK. Free pt-odn or pt-odn complexed with nonglycosylated pLK gave no inhibition at concentrations of < or = 2 microM. Two control pt-odn (one was targeted against an unrelated gene not present in these cells, gag(HIV), and the other had a randomized sequence) gave no inhibition of ICAM-1 expression in the presence or absence of pLK carrying fucose residues at concentrations of < or = 2 microM. When complexed with pLK carrying 100 fucose residues, the amount of cell-associated pt-odn was increased by 15-fold compared with the free pt-odn. Nongycosylated pLK also increased the amount of cell-associated pt-odn by >10 fold but did not alter the biological activity. These results demonstrate clearly the potential of glycosylated pLK as a pt-odn transporter.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8967969

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  8 in total

1.  Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides.

Authors:  C Pichon; M B Roufaï; M Monsigny; P Midoux
Journal:  Nucleic Acids Res       Date:  2000-01-15       Impact factor: 16.971

2.  Delivery of oligonucleotides into mammalian cells by anionic peptides: comparison between monomeric and dimeric peptides.

Authors:  I Freulon; A C Roche; M Monsigny; R Mayer
Journal:  Biochem J       Date:  2001-03-15       Impact factor: 3.857

3.  Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.

Authors:  E G Marcusson; B Bhat; M Manoharan; C F Bennett; N M Dean
Journal:  Nucleic Acids Res       Date:  1998-04-15       Impact factor: 16.971

4.  Pseudoproteoglycan (pseudoPG) probes that simulate PG macromolecular structure for screening and isolation of PG-binding proteins.

Authors:  Keiko Nakagawa; Kosuke Nakamura; Yuji Haishima; Makiko Yamagami; Kana Saito; Hiromi Sakagami; Haruko Ogawa
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

5.  Use of ribozymes and antisense oligodeoxynucleotides to investigate mechanisms of drug resistance.

Authors:  D Byrne; C Daly; R Nicamhlaoibh; A Howlett; K Scanlon; M Clynes
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

6.  Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells.

Authors:  John J Turner; Gabriela D Ivanova; Birgit Verbeure; Donna Williams; Andrey A Arzumanov; Saïd Abes; Bernard Lebleu; Michael J Gait
Journal:  Nucleic Acids Res       Date:  2005-11-30       Impact factor: 16.971

7.  Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic.

Authors:  Pedro M D Moreno; Ana P Pêgo
Journal:  Front Chem       Date:  2014-10-14       Impact factor: 5.221

Review 8.  Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.

Authors:  Alexander Batista-Duharte; Luis Sendra; Maria José Herrero; Damiana Téllez-Martínez; Iracilda Zeppone Carlos; Salvador Francisco Aliño
Journal:  Biomolecules       Date:  2020-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.